Lymphoma clinical trials in Kansas

15 actively recruiting lymphoma trials at 13 sites across Kansas.

Data from ClinicalTrials.gov · last refreshed 2026-07-07

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Payments from the drug maker running this trial to its lead doctors

CMS Open Payments · 2024

BeOne Medicines funds and runs this clinical trial (NCT05100862). In 2024, BeOne Medicines and 1 other company reported paying the doctors leading the trial a total of $4,827,812 for research work on this study.

Who paid

BeiGene, Ltd. $4,687,730
BeiGene USA, Inc. $140,082

Paid for research work on this trial

CHIJIOKE NZE $460,483
PORNCHAI JONGLERTHAM(oncologist on CancerDrs) $402,494
STEVEN MCCUNE(oncologist on CancerDrs) $379,879
BEI HU(oncologist on CancerDrs) $332,245
DAVID BERZ(oncologist on CancerDrs) $292,543

Questions a patient might reasonably ask

Who is funding this trial, and how does the funding company stand to benefit if the trial succeeds?
Does my oncologist have a financial relationship with the trial sponsor outside of this trial?
Are there non-industry-sponsored trials (NIH, cooperative group) for my condition I should consider?
What are the alternative standards of care I should compare against enrolling here?

Research payments are not, by themselves, a conflict — paying for legitimate trial work is how drug development gets funded. The purpose of Sunshine Act disclosure is to give patients the context, not to make the decision for them.

Source: CMS Open Payments · ClinicalTrials.gov · Dispute process · How we compute this

As displayed on 2026-04-21. Corrections flow from the manufacturer through CMS and are adopted on our next refresh.

Phase 3 Recruiting Academic/Other

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

This phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Inotuzumab ozogamicin is a monocl…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT03150693

Sites in Kansas:

Central Care Cancer Center - Garden City — Garden City, Kansas
Central Care Cancer Center - Great Bend — Great Bend, Kansas
University of Kansas Cancer Center — Kansas City, Kansas
Lawrence Memorial Hospital — Lawrence, Kansas
University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas

View on ClinicalTrials.gov →

Phase 3 Recruiting NIH

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05675410

Sites in Kansas:

Wesley Medical Center — Wichita, Kansas

View on ClinicalTrials.gov →

Phase 3 Recruiting Academic/Other

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT05976763

Sites in Kansas:

HaysMed — Hays, Kansas
University of Kansas Cancer Center — Kansas City, Kansas
Lawrence Memorial Hospital — Lawrence, Kansas
Veteran Administration Eastern Kansas Healthcare — Leavenworth, Kansas
The University of Kansas Cancer Center - Olathe — Olathe, Kansas

View on ClinicalTrials.gov →

Phase 3 Recruiting Network

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

This phase III trial compares the effect of high dose chemotherapy and the patients' own (autologous) stem cells to observation only in patients with peripheral T-cell lymphoma who achieved a complete response after initial chemotherapy. U…

Sponsor: Eastern Cooperative Oncology Group

NCT ID: NCT06724237

Sites in Kansas:

University of Kansas Cancer Center — Kansas City, Kansas
University of Kansas Cancer Center-Overland Park — Overland Park, Kansas
University of Kansas Hospital-Westwood Cancer Center — Westwood, Kansas

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R\^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free surviv…

Sponsor: BeOne Medicines

NCT ID: NCT05100862

Sites in Kansas:

Cotton Oneil Cancer Center — Topeka, Kansas
Cancer Center of Kansas — Wichita, Kansas

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's choice in participants with relapsed/refractory follicular lymph…

Sponsor: Celgene

NCT ID: NCT06911502

Sites in Kansas:

Local Institution - 0216 — Westwood, Kansas

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Industry

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancie…

Sponsor: BeOne Medicines

NCT ID: NCT06634589

Sites in Kansas:

The University of Kansas Cancer Center — Westwood, Kansas

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Industry

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

The purpose of this study is to establish the safety of novel dosing and ramp-up schedules for sonrotoclax in participants with hematological malignancies.

Sponsor: BeOne Medicines

NCT ID: NCT06697184

Sites in Kansas:

The University of Kansas Cancer Center — Westwood, Kansas

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transplantation for hematologic malignancies.

Sponsor: Orca Biosystems, Inc.

NCT ID: NCT03802695

Sites in Kansas:

The University of Kansas Hospital — Kansas City, Kansas

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)

Sponsor: PeproMene Bio, Inc.

NCT ID: NCT05370430

Sites in Kansas:

University of Kansas Hospital — Kansas City, Kansas

View on ClinicalTrials.gov →

Phase 1 Recruiting Academic/Other

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

Gamma delta T-cells are part of the innate immune system with the ability to recognize malignant cells and kill them. This study uses gamma delta T-cells to maximize the anti-tumor response and minimize graft versus host disease (GVHD) in …

Sponsor: University of Kansas Medical Center

NCT ID: NCT03533816

Sites in Kansas:

University of Kansas Cancer Center — Westwood, Kansas

View on ClinicalTrials.gov →

Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology

NCT ID: NCT05334069

Sites in Kansas:

Central Care Cancer Center - Garden City — Garden City, Kansas
Central Care Cancer Center - Great Bend — Great Bend, Kansas
Veteran Administration Eastern Kansas Healthcare — Leavenworth, Kansas
Mercy Hospital Pittsburg — Pittsburg, Kansas
Cotton O'Neil Cancer Center / Stormont Vail Health — Topeka, Kansas

View on ClinicalTrials.gov →

Recruiting Network

Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors

This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer …

Sponsor: ECOG-ACRIN Cancer Research Group

NCT ID: NCT06002828

Sites in Kansas:

Central Care Cancer Center - Garden City — Garden City, Kansas
Central Care Cancer Center - Great Bend — Great Bend, Kansas
HaysMed — Hays, Kansas
University of Kansas Cancer Center — Kansas City, Kansas
Lawrence Memorial Hospital — Lawrence, Kansas

View on ClinicalTrials.gov →

Recruiting Network

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.

Sponsor: Center for International Blood and Marrow Transplant Research

NCT ID: NCT01351545

Sites in Kansas:

University of Kansas — Westwood, Kansas

View on ClinicalTrials.gov →

Recruiting Academic/Other

Healthy Weight Intervention Families During ALL Treatment: NOURISH-ALL

The purpose of this study is to conduct a single arm pilot of the NOURISH-ALL (Nourishing Our Understanding of Role modeling to Improve Support and Health in Acute Lymphoblastic Leukemia) intervention focused on three components of partici…

Sponsor: University of Kansas Medical Center

NCT ID: NCT06050850

Sites in Kansas:

University of Kansas Medical Center — Kansas City, Kansas

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-07